---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-132458"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T09:51:47.610379+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA grants Fast Track designation to Corbus' CRB-701 for cervical cancer

## Summary
- CRB-701 is a next-generation Nectin-4 ADC with site-specific cleavable linker, MMAE payload, DAR 2.
- Company completed dose-escalation enrollment for Phase 1 trial in US/Europe (NCT06265727).
- First clinical data from dose-escalation study expected in Q1 2025.
- Fast Track designation aims to speed development and review for unmet medical need in metastatic cervical cancer.

## SEC filing metadata
- accession: 0000950170-24-132458
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024132458/0000950170-24-132458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024132458/crbp-20241203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-132458
- JSON: https://secwatch.observer/filing/0000950170-24-132458.json
- Plain text: https://secwatch.observer/filing/0000950170-24-132458.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.